SCNI — Scinai Immunotherapeutics Ltd.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1611747 ·
Last close
$0.25
Market Cap
$1.30M
52W High
$1.05
52W Low
$0.24
ADV30
384,013
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 489,000 | -1,118,000 | -2,467,000 | 3,577,000 | 17,588,000 | 2,963,000 | 5,827,000 |
| Dec 2025 | — | — | — | — | 11,626,000 | 1,661,000 | 3,523,000 |
| Jun 2025 | — | — | — | — | 11,840,000 | 989,000 | 3,982,000 |
| Mar 2025 | 586,000 | 228,000 | -1,568,000 | -1,557,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,114,000
Investing CF
$-4,000
Financing CF
$2,008,000
CapEx
$-4,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$8.40
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-125,846,000
Inventory
—
Receivables
$168,000
ST Investments
—
EBIT TTM
$10,173,000
Pretax Income TTM
$8,252,000
Interest Exp TTM
$1,921,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,214,000
EBITDA
$-6,918,000
Free Cash Flow
$-3,117,000
Enterprise Value
$7,072,156
Total Cash
$2,963,000
Total Debt
$3,496,000
Shares Out
5,169,383
Trailing EPS
$1.75
Book Value
$1.74
ROE
-29.2%
ROA
-35.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,311,000 | -7,542,000 | -8,307,000 | 11,626,000 | 3,523,000 | — | -6,031,000 |
| Dec 2024 | 658,000 | -8,638,000 | 4,796,000 | 13,448,000 | 3,471,000 | — | -6,335,000 |
| Dec 2023 | 0 | -9,706,000 | -6,500,000 | 17,472,000 | 22,041,000 | — | -9,382,000 |
| Dec 2022 | 0 | -11,061,000 | -5,796,000 | 27,067,000 | 28,827,000 | — | -7,265,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABPO | Abpro Holdings, Inc. | $1.14M | $0.19 | — |
| AGTX | Agentix Corp. | $801.3K | $0.02 | — |
| CERO | CERO THERAPEUTICS HOLDINGS, INC. | $676.7K | $0.01 | — |
| VIVS | VivoSim Labs, INC. | $2.54M | $0.88 | — |
| CLDI | Calidi Biotherapeutics, Inc. | $2.72M | $0.14 | — |
News headlines (Yahoo Finance, 1h cache)
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
2026-06-10 11:55 · Yahoo
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
2026-05-20 11:00 · Yahoo
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
2026-05-15 11:30 · Yahoo
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
2026-04-24 12:00 · Yahoo
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
2026-04-06 11:00 · Yahoo
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
2026-04-01 11:00 · Yahoo
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
2026-03-19 11:50 · Yahoo
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
2026-03-16 20:05 · Yahoo
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
2026-03-02 14:20 · Yahoo
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
2026-02-25 13:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.